XML 26 R16.htm IDEA: XBRL DOCUMENT
v3.22.1

Share-Based Compensation | 3 Months Ended
--- | ---
Mar. 31, 2022
Share-based Payment Arrangement [Abstract] |
Share-Based Compensation | Note 10. Share-based Compensation After the Silver Lake Transaction and prior to the IPO, all share-based awards were issued by Fastball Holdco, L.P., the Company’s previous parent company under individual grant agreements and the partnership agreement of such parent company (collectively the “Successor Plan”). Share-based compensation expense is recognized in cost of services, product and technology expense, and selling, general, and administrative expense, in the accompanying condensed consolidated statements of operations and comprehensive income (loss) as follows (in thousands):
|  | Three Months Ended March 31, 2022 |  |  | Three Months Ended March 31, 2021 |
Share-based compensation expense |  |  |  |  |  |
Cost of services |  | $ | 274 |  |  | $ | 33 |
Product and technology expense |  |  | 204 |  |  |  | 54 |
Selling, general, and administrative expense |  |  | 1,381 |  |  |  | 475 |
Total share-based compensation expense |  | $ | 1,859 |  |  | $ | 562 |
Successor Plan Awards issued under the Successor Plan consist of options and profits interests and vest based on two criteria (50% each): (1) Time — awards vest over five years at a rate of 20% per year; and (2) Performance — awards vest based upon a combination of the five year time vesting, subject to the Company’s investors receiving a targeted money-on-money return. Options issued under the Successor Plan generally expire ten years after the grant date. No awards were issued under the plan during the period from January 1, 2021 through March 31, 2021. In connection with the Company’s IPO, the Company’s parent was dissolved. Awards issued by the Company’s parent were converted in accordance with non-discretionary anti-dilution provisions of the Successor grants as follows: • All vested outstanding profits interest grants issued by the Company’s parent were converted to common stock in the Company and all unvested outstanding profits interest grants issued by the Company’s parent were converted to restricted stock in the Company under the 2021 Omnibus Incentive Plan (the “2021 Equity Plan”). The number of common stock and restricted stock shares issued to each profits interest holder was ratably adjusted to preserve the fair value of the awards. Additionally, the vesting conditions and equity classification of the awards remained unchanged as a result of the conversion. • All outstanding stock option grants issued by the Company’s parent were converted into stock options issued by the Company under the terms of the individual grant agreements. The number of options granted and the strike price of the options was ratably adjusted using an exchange ratio calculated to preserve the fair value of the awards. Additionally, the vesting, vesting conditions, and equity classification of the awards remained unchanged as a result of the conversion.
|  |  | Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
December 31, 2021 | Grants outstanding |  |  | 3,519,563 |  |  | $ | 6.66 |  |  |  |  |
| Grants exercised |  |  | (76,968 | ) |  | $ | 6.75 |  |  |  |  |
| Grants cancelled/forfeited |  |  | — |  |  | $ | — |  |  |  |  |
March 31, 2022 | Grants outstanding |  |  | 3,442,595 |  |  | $ | 6.66 |  |  | 7.9 Years |  | $46.6 million
March 31, 2022 | Grants vested |  |  | 933,896 |  |  | $ | 6.64 |  |  | 7.9 Years |  | $12.7 million
March 31, 2022 | Grants unvested |  |  | 2,508,699 |  |  | $ | 6.67 |  |  |  |  |
2021 Equity Plan In connection with the IPO, the Company adopted the 2021 Equity Plan. The 2021 Equity Plan is intended to provide a means through which to attract and retain key personnel and to provide a means whereby our directors, officers, employees, consultants and advisors can acquire and maintain an equity interest in us, or be paid incentive compensation, including incentive compensation measured by reference to the value of our common stock, thereby strengthening their commitment to our welfare and aligning their interests with those of our stockholders. The 2021 Equity Plan provides for the grant of awards of stock options, stock appreciation rights, restricted shares, and restricted stock units, and other equity-based or cash-based awards as determined by the Company’s Compensation Committee. The 2021 Equity Plan initially had a total of 17,525,000 shares of common stock reserved. The number of reserved shares automatically increases on the first day of each calendar year commencing on January 1, 2022 and ending on January 1, 2030, in an amount equal to the lesser of (x) 2.5% of the total number of shares of common stock outstanding on the last day of the immediately preceding calendar year and (y) a number of shares as determined by the Board of Directors. As of March 31, 2022, 14,315,549 shares were available for issuance under the 2021 Equity Plan. Stock Options Stock options issued immediately prior to the IPO vest based on two criteria (50% each): (1) Time — awards vest over five years at a rate of 20% per year; and (2) Performance — awards vest based upon a combination of the five year time vesting, subject to the Company’s investors receiving a targeted money-on-money return. Stock options issued after the IPO vest annually, generally over four to five years. Stock options generally expire ten years after the grant date. A summary of the option activity for the three months ended March 31, 2022 is as follows:
|  |  | Options |  |  | Weighted Average Exercise Price |  |  | Weighted Average Remaining Contractual Term |  | Aggregate Intrinsic Value
December 31, 2021 | Grants outstanding |  |  | 3,714,540 |  |  | $ | 15.33 |  |  |  |  |
| Grants issued |  |  | 42,950 |  |  | $ | 16.85 |  |  |  |  |
March 31, 2022 | Grants outstanding |  |  | 3,757,490 |  |  | $ | 15.35 |  |  | 9.3 Years |  | $18.2 million
March 31, 2022 | Grants vested |  |  | 966,835 |  |  | $ | 15.00 |  |  | 9.2 Years |  | $5.0 million
March 31, 2022 | Grants unvested |  |  | 2,790,655 |  |  | $ | 15.47 |  |  |  |  |
The fair value for stock options granted for the three months ended March 31, 2022 was estimated at the date of grant using the Black-Scholes option-pricing model with the following weighed average assumptions:
|  | Options |
Expected stock price volatility |  |  | 34.36 | %
Risk-free interest rate |  |  | 2.13 | %
Expected term (in years) |  |  | 6.0 |
Estimated fair-value of the underlying unit |  | $ | 16.85 |
Restricted Stock Units Restricted stock units (“RSU”) vest annually, generally over three to five years. A summary of the RSU activity for the three months ended March 31, 2022 is as follows:
|  |  | Shares |  |  | Weighted Average Grant Date Fair Value |
December 31, 2021 | Nonvested RSUs |  |  | 340,875 |  |  | $ | 17.19 |
| Granted |  |  | 15,528 |  |  | $ | 16.85 |
| Vested |  |  | — |  |  | $ | — |
March 31, 2022 | Nonvested RSUs |  |  | 356,403 |  |  | $ | 17.17 |
Restricted Stock The following table summarizes the restricted stock issued by the Company. These include grants of unvested Successor profits interests grants that were converted into restricted stock as described above, as well as restricted stock issued to new recipients. The restricted stock granted as a result of the conversion of Successor profits interests retain the vesting attributes (including original service period vesting start date) of the original award. A summary of the restricted stock activity for the three months ended March 31, 2022 is as follows:
|  |  | Shares |  |  | Weighted Average Grant Date Fair Value |
December 31, 2021 | Nonvested restricted stock |  |  | 2,613,359 |  |  | $ | 3.85 |
| Granted |  |  | — |  |  | $ | — |
| Vested |  |  | (332,059 | ) |  | $ | 3.85 |
March 31, 2022 | Nonvested restricted stock |  |  | 2,281,300 |  |  | $ | 3.85 |
As of March 31, 2022, the Company had approximately $35.3 million of unrecognized pre-tax noncash compensation expense, comprised of approximately $8.6 million related to restricted stock, $5.5 million related to restricted stock units, and approximately $21.2 million related to stock options, which the Company expects to recognize over a weighted average period of 3.5 years. 2021 Employee Stock Purchase Plan On June 25, 2021, in connection with the IPO, the Company adopted the First Advantage Corporation 2021 Employee Stock Purchase Plan (“ESPP”) that allows eligible employees to voluntarily make after-tax contributions of up to 15% of such employee’s cash compensation to acquire Company stock during designated offering periods. During each offering period, there will be one six-month purchase period, which will have the same duration and coincide with the length of the offering period. During the holding period, ESPP purchased shares are not eligible for sale or broker transfer. No purchases have been made under the ESPP as of March 31, 2022.

X
- Definition The entire disclosure for share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 718 -URI http://asc.fasb.org/topic&trid=2228938 + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration